|
A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). |
|
|
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - Bayer; Novartis; Roche/Genentech |
|
|
Consulting or Advisory Role - Lilly |
Research Funding - Genentech (Inst); Sanofi (Inst) |
|
|
|
Honoraria - Bayer Yakuhin |
|
|
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Proacta |
|
|
|
|
|
Employment - Roche/Genentech |
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
|
|
Consulting or Advisory Role - Lilly; Nordic Group; Roche/Genentech |
Research Funding - Novartis |